What is Juvenescence?
Juvenescence Limited is a pioneering life sciences company dedicated to developing novel therapies aimed at modifying the aging process and extending healthy human longevity. Founded by a team of experienced drug developers, entrepreneurs, and investors, including Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan, Juvenescence leverages deep expertise in the life sciences sector. The company's strategy involves creating, partnering with, or investing in new ventures focused on longevity-related therapeutics. This is achieved by in-licensing compounds from academic and industrial sources or forming strategic joint ventures. Juvenescence capitalizes on recent scientific breakthroughs in understanding aging biology, seeking to develop treatments that can potentially slow, halt, or even reverse aspects of the aging process.
How much funding has Juvenescence raised?
Juvenescence has raised a total of $256.9M across 4 funding rounds:
Angel/Seed
$50M
Series A
$50M
Series B
$100M
Series C
$56.9M
Angel/Seed (2018): $50M, investors not publicly disclosed
Series A (2018): $50M, investors not publicly disclosed
Series B (2019): $100M supported by Grok Ventures and IPGL
Series C (2020): $56.9M, investors not publicly disclosed
Key Investors in Juvenescence
Grok Ventures
Grok Ventures is a venture capital firm that operates within the Venture Capital & Private Equity industry, likely focusing on strategic investments in innovative companies.
IPGL
IPGL Limited is a private holding company with a history of building and investing in fast-growing businesses across various sectors, including healthcare, suggesting a strategic interest in Juvenescence's longevity focus.
What's next for Juvenescence?
The substantial enterprise-level funding and recent strategic investment indicate that Juvenescence is well-positioned for aggressive expansion and further research and development. This capital infusion is expected to accelerate the company's pipeline of longevity therapies, potentially enabling the progression of multiple compounds through clinical trials. Juvenescence's model of creating and investing in specialized companies suggests a continued focus on identifying and nurturing promising longevity technologies. The company's strategic direction points towards solidifying its market leadership in the burgeoning field of age-related therapeutics, with a clear aim to translate scientific advancements into tangible health benefits for an aging global population.
See full Juvenescence company page
